Earnings pressure on the pharmaceutical business from drug price revisions and the shift to generic drugs
First written in FY2017-Q1. 16 of 31 entries say "Materialised", first in FY2020-Q3. Latest entry: FY2025.
Yakult Honsha moved to the "Worse" side of this theme in 2016, 4 years before the typical company in this theme (2020).
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
17 other companies' latest entry also says "Materialised".
- FY2025MaterialisedAnnual report
「In addition, the official prices of 4 products, including the anticancer drug Campto, were removed from the national drug price list as of the end of March this year.」
As earnings pressure from drug price revisions and the shift to generic drugs continued, the removal of 4 products from the national drug price list and the transfer of sales progressed, with factors contributing to the contraction of the pharmaceuticals business reflected in the actual results. - FY2024-Q2MaterialisedAnnual report
「However, the reduction in the official prices of most of our products in the drug price revision implemented in April affected sales. As a result, consolidated net sales in the Other segment were ¥18,705 million, down 4.0% year on year.」
The reduction in the official prices of most products following the drug price revision affected sales, and sales in the Other segment, including pharmaceuticals, declined 4.0% year on year. - FY2024-Q1MaterialisedAnnual report
「However, sales were affected by the reduction in the prices of most of the company's products in the drug price revision implemented in April.」
The reduction in the official prices of most products following the drug price revision is actually reflected in the impact on pharmaceuticals sales for the first quarter. - FY2023MaterialisedAnnual report
「However, sales were affected by the reduction in the official prices of most of our products in the drug price revision implemented last April and the termination in September of the promotion agreement with Nippon Servier concerning the anticancer drug Onivyde®.」
The reduction in official drug prices and the termination of the promotion agreement for Onivyde® were reflected in the actual results as a decline in pharmaceuticals sales, with sales in the segment declining 24.9% from the previous fiscal year. - FY2023-Q3MaterialisedAnnual report
「As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥10,247 million, down 22.4% year on year.」
Against the backdrop of lower official drug prices, the shift to generic drugs and the end of the promotion agreement, sales in the Pharmaceutical Manufacturing and Marketing segment declined 22.4% year on year, with the earnings pressure reflected in the actual results. - FY2023-Q2MaterialisedAnnual report
「However, the reduction in the official prices of most of our products in the drug price revision implemented in April affected sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥7,233 million, down 16.1% year on year.」
The reduction in the official prices of most products following the drug price revision actually affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 16.1% year on year. - FY2023-Q1MaterialisedAnnual report
「However, the reduction in the official prices of most of our products in the drug price revision implemented in April affected sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥3,855 million, down 11.1% year on year.」
The reduction in the official prices of most products following the April drug price revision affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 11.1% year on year. - FY2022MaterialisedAnnual report
「However, opportunities to use our products declined because of postponed hospital admissions and surgeries, patients refraining from seeking medical care and other factors resulting from COVID-19. In addition, the reduction in the official prices of most of our products in the drug price revision implemented last April affected sales, leaving results at approximately the previous fiscal year's level. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥16,992 million, down 6.2% from the previous fiscal year.」
The decline in opportunities to use pharmaceuticals because of COVID-19, combined with lower official drug prices, resulted in sales in the Pharmaceutical Manufacturing and Marketing segment declining 6.2% from the previous fiscal year. - FY2022-Q3MaterialisedAnnual report
「However, opportunities to use our products declined because of postponed hospital admissions and surgeries, patients refraining from seeking medical care and other factors resulting from COVID-19. In addition, the reduction in the official prices of most of our products in the drug price revision implemented last April affected sales, leaving results at approximately the previous year's level.」
The decline in opportunities to use pharmaceuticals because of COVID-19 and lower official drug prices continued, and sales in the Pharmaceutical Manufacturing and Marketing segment were ¥13,197 million, down 2.7% year on year. - FY2022-Q2MaterialisedAnnual report
「However, opportunities to use our products declined because of postponed hospital admissions and surgeries, patients refraining from seeking medical care and other factors resulting from COVID-19. In addition, the reduction in the official prices of most of our products in the drug price revision implemented in April affected sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥8,618 million, down 3.4% year on year.」
The decline in opportunities to use the products at medical institutions because of COVID-19 and lower official drug prices continued, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 3.4% year on year. - FY2022-Q1MaterialisedAnnual report
「However, as the COVID-19 pandemic spread, opportunities to use our products declined because of postponed hospital admissions and surgeries, patients refraining from seeking medical care and other factors. In addition, the reduction in the official prices of most of our products in the drug price revision implemented in April affected sales.」
The decline in opportunities to use the products at medical institutions because of COVID-19 and the reduction in official drug prices following the April drug price revision continued to be reflected in pharmaceuticals sales. - FY2021MaterialisedAnnual report
「However, as the COVID-19 pandemic spread, opportunities to use our products declined because of postponed hospital admissions and surgeries, patients refraining from seeking medical care and other factors. In addition, the reduction in the official prices of most of our products in the drug price revision implemented last April affected sales.」
The decline in opportunities to use the products at medical institutions because of the pandemic, combined with lower official drug prices, resulted in sales of ¥18,123 million in the Pharmaceutical Manufacturing and Marketing segment, down 7.9% from the previous fiscal year. - FY2021-Q3WorsenedAnnual report
「However, as the COVID-19 pandemic spread, limited medical resources were concentrated on patients infected with COVID-19, reducing opportunities to use our products because of postponed hospital admissions and surgeries, patients refraining from seeking medical care and other factors. In addition, the reduction in the official prices of most of our products in the drug price revisions implemented by last April affected sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥13,568 million, down 12.8% year on year.」
In addition to postponed hospital admissions and surgeries and patients refraining from seeking medical care because of COVID-19, the impact of lower official drug prices also contributed to the decline, and sales in the Pharmaceutical Manufacturing and Marketing segment fell 12.8% year on year. - FY2021-Q2MaterialisedAnnual report
「However, sales were affected by the impact of the COVID-19 pandemic and the reduction in the official prices of most of our products in the drug price revisions implemented last October and this April.」
The COVID-19 pandemic and reductions in official drug prices following the October 2019 and April 2020 drug price revisions affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment were ¥8,925 million, down 14.2% year on year. - FY2021-Q1MaterialisedAnnual report
「However, sales were affected by the impact of the COVID-19 pandemic and the reduction in the official prices of most of our products in the drug price revisions implemented last October and this April.」
The COVID-19 pandemic and reductions in official drug prices following the October 2019 and April 2020 drug price revisions affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 18.6% year on year. - FY2020MaterialisedAnnual report
「However, the revision of the national drug price schedule implemented in connection with the consumption tax increase reduced the official prices of most of our products, affecting sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥19,670 million, down 9.3% from the previous fiscal year.」
The reduction in the official prices of most products following the revision of the national drug price schedule affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 9.3% from the previous fiscal year. - FY2020-Q3MaterialisedAnnual report
「However, the reduction in the official prices of most of our products following the revision of the national drug price schedule implemented last October affected sales.」
The reduction in the official prices of most products following the October 2019 revision of the national drug price schedule actually affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment were ¥15,561 million, down 8.0% year on year. - FY2020-Q2WorsenedAnnual report
「However, the gradual shift to generic drugs affected sales.」
As the shift to generic drugs progressed, sales in the Pharmaceutical Manufacturing and Marketing segment were ¥10,404 million, down 6.3% year on year. - FY2020-Q1RestatedAnnual report
「However, the revision of the national drug price schedule implemented last April reduced the official prices of most of our products, significantly affecting sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥5,460 million, down 3.4% year on year.」
The company continues to describe the reduction in the official prices of most products following the revision of the national drug price schedule and its impact on pharmaceuticals sales. Sales declined 3.4% year on year. The original text quantifies the impact, which is reflected in the actual results. - FY2019WorsenedAnnual report
「However, the revision of the national drug price schedule implemented last April reduced the official prices of most of our products, significantly affecting sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥21,696 million, down 15.5% from the previous fiscal year.」
The official prices of most products were reduced following the revision of the national drug price schedule, and sales in the pharmaceuticals business declined 15.5% from the previous fiscal year. The company also states that annual drug price revisions are expected from April 2018 onward. - FY2019-Q3WorsenedAnnual report
「However, the revision of the national drug price schedule implemented last April reduced the official prices of most of our products, significantly affecting sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥16,920 million, down 16.5% year on year.」
The reduction in the official prices of most products following the revision of the national drug price schedule significantly affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 16.5% year on year. - FY2019-Q2WorsenedAnnual report
「However, the revision of the national drug price schedule implemented in April reduced the official prices of most of our products, significantly affecting sales. As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥11,100 million, down 16.2% year on year.」
The reduction in the official prices of most products following the revision of the national drug price schedule significantly affected sales, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 16.2% year on year. - FY2019-Q1WorsenedAnnual report
「As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥5,651 million, down 15.6% year on year.」
The official prices of most products were reduced following the revision of the national drug price schedule, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 15.6% year on year. - FY2018WorsenedAnnual report
「Consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥25,661 million, down 7.8% from the previous fiscal year.」
Against the backdrop of the shift to generic drugs and lower official drug prices, full-year sales in the pharmaceuticals business declined 7.8% year on year. The company also states that drug price revisions are expected to be implemented annually from April 2018 onward. - FY2018-Q3RestatedAnnual report
「Although the number of medical institutions switching to generic drugs has been trending upward since generic versions of ELOXATIN were launched, we continued efforts to have them choose ELOXATIN by drawing on our strengths as the developer of the originator drug, including our ability to provide information and the trust we have built with healthcare professionals.」
The company continues to describe the increasing trend among medical institutions to switch to generic drugs and its response through its ability to provide information and relationships of trust with healthcare professionals. - FY2018-Q2RestatedAnnual report
「Although the number of medical institutions switching to generic drugs has been trending upward since generic versions of ELOXATIN were launched, we continued efforts to have them choose ELOXATIN by drawing on our strengths as the developer of the originator drug, including our ability to provide information and the trust we have built with healthcare professionals.」
The company continues to describe the increasing trend among medical institutions to switch to generic drugs and its response through its ability to provide information and relationships of trust with healthcare professionals. Sales in the Pharmaceutical Manufacturing and Marketing segment declined 8.4% year on year. - FY2018-Q1RestatedAnnual report
「As a result, sales in the Pharmaceutical Manufacturing and Marketing segment were ¥6,698 million, down 10.9% year on year.」
The trend toward switching to generic drugs and the earnings pressure following the reduction in official drug prices have continued, and sales in the Pharmaceutical Manufacturing and Marketing segment declined 10.9% year on year. - FY2017WorsenedAnnual report
「However, following last April's drug price revision, the official prices of our products were substantially reduced, placing us in a difficult position.」
Against the backdrop of lower official drug prices following the drug price revision and the shift to generic drugs, full-year sales in the Pharmaceutical Manufacturing and Marketing business declined 20.0% year on year. - FY2017-Q3RestatedAnnual report
「However, following last April's drug price revision, the official prices of our products were substantially reduced, placing us in a difficult position.」
The company continues to describe earnings pressure on the pharmaceuticals business from lower official drug prices and the shift to generic drugs. Sales in the Pharmaceutical Manufacturing and Marketing business declined 19.1% year on year. - FY2017-Q2WorsenedAnnual report
「As a result, consolidated net sales in the Pharmaceutical Manufacturing and Marketing segment were ¥14,453 million, down 19.2% year on year.」
While the discussion continues to describe difficulties resulting from drug price revisions, sales in the Pharmaceutical Manufacturing and Marketing segment declined 19.2% year on year. - FY2017-Q1First statedAnnual report
「Since generic versions of ELOXATIN were launched, the shift to generic drugs has progressed. However, we have continued efforts to encourage customers to choose ELOXATIN, leveraging our strength in providing information as the developer of the originator drug. Nevertheless, the April drug price revision resulted in a substantial reduction in the official prices of our products, putting the business under pressure.」
The shift to generic drugs and the significant reduction in official drug prices following the April drug price revision are described as actual business pressures.